Corcept Therapeutics Inc. (CORT)
Health Care ยท Pharmaceutical Preparations
Corcept Therapeutics Inc. (CORT) is listed on Nasdaq, where its shares have traded since April 14, 2004. SentiSense covers Corcept Therapeutics Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Joseph K. Belanoff is its chief executive officer. The company reports 730 employees, and its corporate website is www.corcept.com.
About Corcept Therapeutics Inc.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 411 institutions reported holding CORT, with 82.2 million shares worth $7.1 billion in aggregate. The largest reported holders were BlackRock, Vanguard and Ingalls & Snyder. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on CORT
- CORT sentiment: whether news and social coverage of Corcept Therapeutics Inc. leans bullish or bearish, and the stories driving it.
- CORT ownership: all 411 reporting institutions, plus insider and congressional trades.
- CORT financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Corcept Therapeutics Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Corcept Therapeutics Inc. do?
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone.
What sector is CORT in?
SentiSense classifies Corcept Therapeutics Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does CORT stock trade?
Corcept Therapeutics Inc. (CORT) is listed on Nasdaq, where its shares have traded since April 14, 2004.
Who is the CEO of Corcept Therapeutics Inc.?
Joseph K. Belanoff is the chief executive officer of Corcept Therapeutics Inc..